Markers For Assessing the Susceptibility of Cancer to Survivin-Targeting miRNA Treatment

Abstract

The present invention relates to the use of miRNA treatment of survivin-positive cancer cells to increase sensitivity of cells to chemotherapy.

1 . A method of inhibiting a survivin-positive cancer cell comprising contacting said cell with miR-203 and/or miR-542-3p in combination with an anti-cancer chemotherapeutic agent. 
     
     
         2 . The method of  claim 1 , wherein said cancer cell is contacted with miR-203 and not miR-542-3p. 
     
     
         3 . The method of  claim 1 , wherein said cancer cell is contacted with miR-542-3p and not miR-203. 
     
     
         4 . The method of  claim 1 , wherein said cancer cell is contacted with miR-203 and miR-542-3p. 
     
     
         5 . The method of  claim 1 , wherein said anti-cancer chemotherapeutic agent is an anti-mitotic agent, alkylating agent, and cytotoxic antibiotic. 
     
     
         6 - 8 . (canceled) 
     
     
         9 . The method of  claim 1 , wherein said cancer cell is a breast cancer cell, prostate cancer cell, ovarian cancer cell, lung cancer cell, gastric cancer cell, esophageal cancer cell, and pancreatic cancer cell. 
     
     
         10 . The method of  claim 1 , wherein said cancer cell is a recurrent cancer cell, a metastatic cancer cell or a multi-drug resistant cancer cell. 
     
     
         11 - 13 . (canceled) 
     
     
         14 . The method of  claim 1 , wherein inhibiting comprises inhibiting growth of said cancer cell or killing said cancer cell. 
     
     
         15 . (canceled) 
     
     
         16 . The method of  claim 1 , further comprising contacting said cancer cell with an additional anti-cancer therapy. 
     
     
         17 . (canceled) 
     
     
         18 . A method of treating a subject exhibiting a survivin-positive cancer comprising administering to said subject miR-203 and/or miR-542-3p in combination with an anti-cancer chemotherapeutic agent. 
     
     
         19 . The method of  claim 18 , wherein said subject is administered miR-203 and not miR-542-3p. 
     
     
         20 . The method of  claim 18 , wherein said subject is administered miR-542-3p and not miR-203. 
     
     
         21 . The method of  claim 18 , wherein said subject is administered miR-203 and miR-542-3p. 
     
     
         22 . The method of  claim 18 , wherein said anti-cancer chemotherapeutic agent is an anti-mitotic agent, alkylating agent, and cytotoxic antibiotic. 
     
     
         23 . (canceled) 
     
     
         24 . The method of  claim 18 , wherein said cancer is breast cancer, prostate cancer, ovarian cancer, lung cancer, gastric cancer, esophageal cancer, and pancreatic cancer. 
     
     
         25 . The method of  claim 18 , wherein said cancer is a recurrent cancer, a metastatic cancer or a multi-drug resistant cancer. 
     
     
         26 - 28 . (canceled) 
     
     
         29 . The method of  claim 18 , wherein inhibiting comprises slowing tumor growth. 
     
     
         30 . The method of  claim 18 , wherein inhibiting comprises delaying tumor metastasis. 
     
     
         31 . The method of  claim 18 , wherein inhibiting comprises killing one or more cells of said cancer. 
     
     
         32 . The method of  claim 18 , further comprising treating said subject with an additional anti-cancer therapy. 
     
     
         33 - 36 . (canceled)